symbol,statement_type,period_end,line_item,value
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.206214
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Normalized EBITDA,3034200000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Total Unusual Items,0.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,557800000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,15421000000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,EBITDA,3034200000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,EBIT,2476400000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Interest Income,-358700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Interest Expense,358700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Interest Income,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Normalized Income,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Total Expenses,21557500000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Diluted Average Shares,91270000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Basic Average Shares,91270000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Diluted EPS,18.35
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Basic EPS,18.35
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income,1681600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Minority Interests,615000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,1681000000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,1681000000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Tax Provision,436700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Pretax Income,2117700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,163600000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Special Income Charges,0.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Other Special Charges,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Write Off,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-358700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,358700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Operating Income,2312800000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Operating Expense,6136500000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Other Operating Expenses,4457700000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,557800000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Amortization,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,557800000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Selling General And Administration,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Gross Profit,8449300000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Cost Of Revenue,15421000000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Total Revenue,23870300000.0
AARTIDRUGS.NS,income,2025-03-31 00:00:00,Operating Revenue,23870300000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.271473
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Normalized EBITDA,3205000000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,514500000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,16777200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,EBITDA,3205000000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,EBIT,2690500000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Interest Income,-335200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Interest Expense,335200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Interest Income,24955000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Normalized Income,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Total Expenses,22635700000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,600000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Diluted Average Shares,91940000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Basic Average Shares,91940000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Diluted EPS,18.56
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Basic EPS,18.56
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income,1714200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Minority Interests,-1725000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,1715900000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,1715900000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Tax Provision,639400000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Pretax Income,2355300000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,40300000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Other Special Charges,1834000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Write Off,21875000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-335200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,43730000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,335200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,24955000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Operating Income,2650100000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Operating Expense,5858500000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Other Operating Expenses,4320600000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,514500000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Amortization,3989000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,514500000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Selling General And Administration,718722000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,576887000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,General And Administrative Expense,141835000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Gross Profit,8508600000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Cost Of Revenue,16777200000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Total Revenue,25285800000.0
AARTIDRUGS.NS,income,2024-03-31 00:00:00,Operating Revenue,25285800000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-3947159.5
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.2579
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Normalized EBITDA,3093300000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Total Unusual Items,-15305000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-15305000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1663088000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,503241000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,22225987000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,EBITDA,3077995000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,EBIT,2574753000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Interest Income,-364388000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Interest Expense,332932000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Interest Income,6992000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Normalized Income,1674445840.5
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1663088000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Total Expenses,24392183000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,600000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Diluted Average Shares,92600000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Basic Average Shares,92600000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Diluted EPS,17.97
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Basic EPS,17.97
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,1663088000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,1663088000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income,1663088000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Minority Interests,-484000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,1663572000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,1663572000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Tax Provision,578249000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Pretax Income,2241821000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,-42003000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Special Income Charges,-15305000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Other Special Charges,
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Write Off,15305000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-364388000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,38448000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,332932000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,6992000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Operating Income,2663495000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Operating Expense,2166196000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Other Operating Expenses,6239000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,503242000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Amortization,648000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,502594000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Selling General And Administration,835934000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,698067000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,General And Administrative Expense,137867000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Gross Profit,4829691000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Cost Of Revenue,22225987000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Total Revenue,27055678000.0
AARTIDRUGS.NS,income,2023-03-31 00:00:00,Operating Revenue,27055678000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-4057719.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.2406
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Normalized EBITDA,3424385000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Total Unusual Items,-16865000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-16865000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,2050386000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,500489000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,19849832000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,EBITDA,3407520000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,EBIT,2907031000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Interest Income,-231909000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Interest Expense,207480000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Interest Income,7169000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Normalized Income,2063193281.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,2050386000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Total Expenses,21908489000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,600000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Diluted Average Shares,92600000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Basic Average Shares,92600000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Diluted EPS,22.142397
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Basic EPS,22.142397
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,2050386000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,2050386000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income,2050386000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Minority Interests,428000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,2049958000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,2049958000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Tax Provision,649593000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Pretax Income,2699551000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,-45632000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Special Income Charges,-16865000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Other Special Charges,
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Write Off,16865000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-231909000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,31598000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,207480000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,7169000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Operating Income,2977969000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Operating Expense,2058657000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Other Operating Expenses,3226000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,500489000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Amortization,407000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,500082000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Selling General And Administration,815937000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,683648000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,General And Administrative Expense,132289000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Gross Profit,5036626000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Cost Of Revenue,19849832000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Total Revenue,24886458000.0
AARTIDRUGS.NS,income,2022-03-31 00:00:00,Operating Revenue,24886458000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Total Unusual Items,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,EBITDA,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,EBIT,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Interest Income,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Interest Expense,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Interest Income,25958000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Normalized Income,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Total Expenses,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,600000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Basic Average Shares,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Diluted EPS,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Basic EPS,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Minority Interests,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Tax Provision,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Pretax Income,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Special Income Charges,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Other Special Charges,-32668000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Write Off,38887000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,32733000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,25958000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Operating Income,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Operating Expense,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Amortization,11755000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Selling General And Administration,744591000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,650196000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,General And Administrative Expense,94395000.0
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Gross Profit,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Total Revenue,
AARTIDRUGS.NS,income,2021-03-31 00:00:00,Operating Revenue,
